This case series included a review of all patients who received at least one dose of T-DM1 in the adjuvant or metastatic setting for treatment of HER2+ breast cancer between January 2013 and October 2020 at the Mayo Clinic. This evidence concerns the gene ERBB2 and breast cancer.